Transcode Therapeutics (RNAZ) Return on Capital Employed (2021 - 2026)
Transcode Therapeutics' (RNAZ) quarterly Return on Capital Employed came in at 27.57% in Q1 2026, up 17338.0% YoY from N/an in Q1 2025, and up 20.87% on a QoQ basis from 34.84% in Q4 2025.
Transcode Therapeutics (RNAZ) Return on Capital Employed (2021 - 2026) Analysis & Trends
Transcode Therapeutics (RNAZ) has 6 years of Return on Capital Employed data on file, last reported at 27.57% in Q1 2026.
- Quarterly Return on Capital Employed rose 17338.0% year-over-year to 27.57% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 27.57% (up 17338.0% YoY) and the FY2025 annual result came in at 34.39%, up 41819.0% from the prior year.
- Return on Capital Employed rose to 27.57% in Q1 2026, from 34.84% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 27.57% in Q1 2026 to a low of 1758.62% in Q1 2023.
- A 5-year average of 469.06% and a median of 451.1% in 2025 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed slumped 171042 bps — and 2024, when it jumped 125294 bps.
- Tracing RNAZ's Return on Capital Employed over 5 years: stood at 341.62% in 2022, then plunged by 35 bps to 461.45% in 2023, then decreased by 19 bps to 550.76% in 2024, then surged by 94 bps to 34.84% in 2025, then climbed by 21 bps to 27.57% in 2026.
- The last three Return on Capital Employed figures came in at 27.57% (Q1 2026), 34.84% (Q4 2025), and 451.1% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 7.88% |
| 10 | Transcode Therapeutics | 2.85 Mn | 2.85 Mn | - | -30.35% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.57% |
| Dec 31, 2025 | -34.84% |
| Sep 30, 2025 | -451.10% |
| Jun 30, 2025 | -159.84% |
| Mar 31, 2025 | -200.95% |
| Dec 31, 2024 | -550.76% |
| Sep 30, 2024 | -699.57% |
| Jun 30, 2024 | -697.04% |
| Mar 31, 2024 | -505.68% |
| Dec 31, 2023 | -461.45% |
| Sep 30, 2023 | -847.40% |
| Jun 30, 2023 | -924.69% |
| Mar 31, 2023 | -1,758.62% |
| Dec 31, 2022 | -341.62% |
| Sep 30, 2022 | -173.12% |
| Jun 30, 2022 | -91.58% |
| Mar 31, 2022 | -48.20% |
| Dec 31, 2021 | -28.46% |
| Sep 30, 2021 | -31.54% |